Apnimed prices upsized IPO at $16, raising $192 million
Apnimed Inc. priced its upsized IPO at $16 per share for 12 million shares, raising $192 million. The stock trades on Nasdaq as APMD starting July 31, 2026. Proceeds support the development of AD109 for obstructive sleep apnea, with a PDUFA date set for February 28, 2027.
*this image is generated using AI for illustrative purposes only.
Apnimed Inc., a late-stage clinical pharmaceutical company focused on sleep-related breathing diseases, priced its upsized initial public offering (IPO) on July 30, 2026, raising $192 million in gross proceeds. The Cambridge, Massachusetts-based firm sold 12,000,000 shares of common stock to the public at $16.00 per share. This capital raise supports the commercialization of its lead candidate, AD109, which targets obstructive sleep apnea (OSA) and has a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027.
The offering is expected to close on or about August 3, 2026, subject to customary closing conditions. Apnimed granted underwriters a 30-day option to purchase an additional 1,800,000 shares at the IPO price, less discounts and commissions. If fully exercised, this option would increase total gross proceeds beyond the initial $192 million. All shares in the offering are being sold by Apnimed itself, not by selling shareholders.
BofA Securities, Evercore ISI, Cantor Fitzgerald & Co., and LifeSci Capital acted as joint book-running managers for the transaction. Registration statements for the offering were filed with the Securities and Exchange Commission (SEC) and became effective on July 30, 2026. The final prospectus is available via the SEC website or through the designated underwriters.
Offering Details
| Metric | Value |
|---|---|
| Shares Offered | 12,000,000 |
| Price Per Share | $16.00 |
| Gross Proceeds | $192 million |
| Over-Allotment Option | 1,800,000 shares |
| Trading Start Date | July 31, 2026 |
| Expected Closing Date | August 3, 2026 |
Clinical Context
Apnimed is developing AD109, a novel oral therapy designed to improve oxygenation in patients with mild, moderate, and severe OSA. The company believes that once-nightly oral drugs can expand treatment reach compared to traditional devices or surgeries. AD109 has completed two Phase 3 clinical trials. The PDUFA date of February 28, 2027, marks the deadline for regulatory decision-making by the FDA regarding the New Drug Application.
What the Numbers Show
The decision to upsize the offering suggests strong investor demand and confidence in Apnimed’s pipeline. Raising $192 million provides substantial runway for the company to navigate the final stages of regulatory approval and prepare for commercial launch. With no revenue disclosed from operations yet, the capital infusion is critical for sustaining development costs until potential market entry post-PDUFA date.
How might the potential FDA approval of AD109 in February 2027 disrupt the current market dominance of CPAP devices for obstructive sleep apnea treatment?
What specific commercialization strategies is Apnimed planning to deploy with the $192 million raised to ensure rapid market adoption of an oral therapy over established device-based treatments?
Will the exercise of the 1.8 million share over-allotment option signal sustained institutional confidence, or could it indicate dilution concerns for early investors?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
